[{"id":"c7430dc9-01ea-42e0-b7c3-86cf71195b7e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01446159","created_at":"2021-01-18T05:59:58.146Z","updated_at":"2024-07-02T16:36:44.570Z","phase":"Phase 1b/2","brief_title":"Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer","source_id_and_acronym":"NCT01446159","lead_sponsor":"MedImmune LLC","biomarkers":" HER-2 • IGF2","pipe":"","alterations":" ","tags":["HER-2 • IGF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e exemestane • dusigitumab (MEDI-573)"],"overall_status":"Completed","enrollment":" Enrollment 188","initiation":"Initiation: 06/13/2011","start_date":" 06/13/2011","primary_txt":" Primary completion: 06/28/2019","primary_completion_date":" 06/28/2019","study_txt":" Completion: 06/28/2019","study_completion_date":" 06/28/2019","last_update_posted":"2020-06-02"},{"id":"357dc3dd-3511-4e3e-92dc-2dae662ea8ca","acronym":"","url":"https://clinicaltrials.gov/study/NCT00816361","created_at":"2021-01-18T03:06:08.124Z","updated_at":"2024-07-02T16:37:02.295Z","phase":"Phase 1","brief_title":"A Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT00816361","lead_sponsor":"MedImmune LLC","biomarkers":" IGF1 • IGF2","pipe":"","alterations":" ","tags":["IGF1 • IGF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dusigitumab (MEDI-573)"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 03/09/2009","start_date":" 03/09/2009","primary_txt":" Primary completion: 09/11/2012","primary_completion_date":" 09/11/2012","study_txt":" Completion: 09/11/2012","study_completion_date":" 09/11/2012","last_update_posted":"2019-03-04"}]